目 公司資料 2 錄 財務概要 主席報告 4 5 管理層討論與分析 7 董事及高級管理層履歷 20 企業管治報告 24 董事會報告 40 獨立核數師報告 67 綜合損益及其他全面收益表 72 綜合財務狀況表 73 綜合權益變動表 75 綜合現金流量表 76 綜合財務報表附註 78 持作投資之物業 166 公司資料 於二零二五年三月二十八日 執行董事 謝粵輝 （主席兼首席執行官） 劉劍雄 （常務副總裁、首席財務官兼公司秘書） 阮杏梅 （首席合規官，於二零二四年十二月十二日獲委任） 非執行董事 姜峰 獨立非執行董事 梁顯治 王皖松 周路明 公司秘書 劉劍雄 授權代表 謝粵輝 劉劍雄 審核委員會 梁顯治 （主席） 周路明 王皖松 提名委員會 周路明 （主席） 謝粵輝 梁顯治 薪酬委員會 中國深圳福田 車公廟天安工業區 天祥大廈1樓A座 王皖松 （主席） 謝粵輝 梁顯治 香港股份過戶登記處 卓佳證券登記有限公司 香港夏愨道16號 遠東金融中心17 樓 網站 www.lifetechmed.com 股份代號 1302 在創業板上市日期 二零一一年十一月十日 由創業板轉往主板上市的日期 二零一三年十一月六日 主要往來銀行 ...

从中证港股通医疗综合指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通医疗综合指数持仓样本的行业来看，医药商业占比46.78%、医疗服务占比24.51%、医疗 耗材占比24.08%、医疗设备占比3.70%、体外诊断占比0.92%。 金融界4月10日消息，上证指数高开震荡，中证港股通医疗综合指数 (港股通医疗，932271)报1310.24 点。 数据统计显示，中证港股通医疗综合指数近一个月下跌15.51%，近三个月上涨7.01%，年至今上涨 1.58%。 据了解，中证港股通行业综合指数系列在中证港股通综合指数样本中，按中证行业分类标准进行分类， 以进入各一、二、三级行业的全部证券作为样本编制指数，形成中证港股通行业综合指数系列，以反映 港股通公司中不同行业证券的整体表现。该指数以2021年12月31日为基日，以3000.0点为基点。 从指数持仓来看，中证港股通医疗综合指数十大权重分别为：阿里健康（14.23%）、京东健康 （14.01%）、国药控股（12.15%）、威高股份（7.98%）、微创医疗（5.06%）、平安好医生 （4.48%）、上海医药（4.05%）、锦欣生殖（3.72%）、 ...

Investment Rating - The report maintains a "Buy" rating for the company, anticipating a price increase of 5% to 15% over the next 6 to 12 months [5][11]. Core Insights - The company achieved a revenue of 1.304 billion yuan in 2024, reflecting a year-on-year growth of 2.9%. However, the gross profit decreased by 1.4% to 981 million yuan, and the net profit attributable to shareholders fell by 15.5% to 222 million yuan [2]. - The core business revenue showed stable growth, with the structural heart disease segment generating 528 million yuan, up 6.4% year-on-year. The left atrial appendage occluder maintained its position as the top domestic brand globally, with a revenue increase of 12.4% [3]. - The international business expanded significantly, with overseas revenue reaching 347 million yuan, a 26% increase year-on-year, accounting for 26.6% of total revenue. The Asian and European markets grew by 33.6% and 18.6%, respectively [3]. Summary by Sections Performance Review - In 2024, the company reported total revenue of 1.304 billion yuan, a slight increase of 2.9% from the previous year. The gross profit was 981 million yuan, down 1.4%, and the net profit attributable to shareholders was 222 million yuan, down 15.5% [2]. Operational Analysis - The structural heart disease business generated 528 million yuan, up 6.4% year-on-year, with the left atrial appendage occluder seeing a 12.4% increase in revenue. The peripheral vascular business also grew by 6.2%, with a notable 8.3% increase in revenue from covered stent products [3]. - The overall gross margin for the year was 75.3%, a decrease of 3.3 percentage points, primarily due to price reductions from procurement policies and an increase in lower-margin product sales [3]. Innovation and R&D - The company invested 303 million yuan in R&D in 2024, with ongoing product development supporting long-term growth. Notably, the aortic covered stent system received regulatory approval in February 2025, providing new treatment options for patients [4]. Profit Forecast and Valuation - The company is expected to see net profits of 337 million yuan, 421 million yuan, and 527 million yuan for 2025, 2026, and 2027, respectively, representing growth rates of 51%, 25%, and 25%. The current price-to-earnings ratio is projected to be 22, 18, and 14 times for the same years [5].

Financial Performance - The total revenue for LifeTech Scientific Corporation for the year ended December 31, 2024, was approximately RMB 1,303.7 million, an increase of about RMB 36.5 million or approximately 2.9% compared to RMB 1,267.2 million in the same period of 2023[3]. - The gross profit for the year ended December 31, 2024, was approximately RMB 981.4 million, a decrease of about 1.4% from RMB 995.6 million in 2023[3]. - The net profit for the year ended December 31, 2024, was approximately RMB 168.5 million, representing an increase of approximately 56.7% from RMB 107.5 million in 2023, primarily due to a reduction in fair value losses related to financial liabilities[3]. - The profit attributable to owners of the company for the year ended December 31, 2024, was approximately RMB 222.4 million, a decrease of about 15.5% from RMB 263.2 million in 2023[3]. - The company reported a basic earnings per share of RMB 5.1 cents for the year ended December 31, 2024, compared to RMB 6.0 cents in 2023[4]. - The company did not declare any final dividend for the year ended December 31, 2024, consistent with 2023[3]. - Revenue from external customers in 2024 reached RMB 1,303,699,000, a 2.6% increase from RMB 1,267,175,000 in 2023[21]. - The pre-tax profit for 2024 was RMB 467,863,000, compared to RMB 379,811,000 in 2023, indicating a growth of 23.1%[24]. Assets and Liabilities - The total assets as of December 31, 2024, amounted to approximately RMB 4,084.7 million, compared to RMB 3,926.2 million as of December 31, 2023[5]. - The net assets as of December 31, 2024, were approximately RMB 3,475.4 million, an increase from RMB 3,324.0 million in 2023[6]. - The total liabilities for the group as of December 31, 2024, were RMB 1,424,949 thousand, compared to RMB 1,372,394 thousand in 2023[18]. - The company’s total liabilities increased to RMB 758.21 million in 2024 from RMB 710.15 million in 2023, indicating a rise of approximately 6.8%[37]. - Cash and cash equivalents decreased by approximately 32.0% from RMB 979.3 million as of December 31, 2023, to approximately RMB 665.8 million as of December 31, 2024[75]. - The current ratio as of December 31, 2024, was approximately 2.86, compared to 2.90 as of December 31, 2023[74]. - The company had no bank borrowings as of December 31, 2024, resulting in a debt-to-equity ratio of zero[76]. Research and Development - Research and development expenses for the year ended December 31, 2024, were approximately RMB 302.9 million, slightly increased from RMB 297.9 million in 2023[4]. - The group’s research and development expenses for the fiscal year 2024 totaled RMB 302,915 thousand, compared to RMB 297,921 thousand in 2023[15]. - The company submitted 321 patent applications and registered 161 patents as of December 31, 2024, with a total of 2,426 valid patent applications submitted[51]. - The company is focused on developing innovative medical devices, including a fourth-generation congenital heart defect occluder and upgrades to the left atrial appendage occluder to meet growing treatment demands[90]. - The company plans to increase R&D investment, focusing on new materials and technologies to drive product innovation and expand production lines[96]. Market Performance - The company’s revenue from the domestic market accounted for approximately 73.4% of total revenue for the fiscal year ending December 31, 2024, down from 78.3% in 2023[46]. - The company’s overseas markets, particularly Asia (excluding mainland China) and Europe, accounted for approximately 11.7% and 10.1% of total revenue, respectively, for the fiscal year ending December 31, 2024[46]. - Revenue from the structural heart disease business was approximately RMB 527.6 million, representing a growth of about 6.4% from RMB 495.7 million in the previous year[54]. - Revenue from the peripheral vascular business was approximately RMB 751.1 million, an increase of about 6.2% from RMB 707.1 million in the previous year[56]. - The company leads the domestic market share in the provision of interventional medical devices for peripheral vascular diseases, with expected continued growth due to aging population and increased disease detection rates[91]. Employee and Operational Costs - Employee costs, including director remuneration, totaled RMB 283,502,000 in 2024, an increase from RMB 247,453,000 in 2023, reflecting a rise of 14.6%[24]. - The company employs 1,392 full-time employees as of December 31, 2024, with total employee costs amounting to approximately RMB 467.9 million, compared to RMB 379.8 million in 2023[94]. - Selling and distribution expenses increased by approximately 28.0% to about RMB 339.6 million, primarily due to increased employee costs and marketing expenses[63]. - Administrative expenses rose by approximately 10.2% to about RMB 164.6 million, mainly due to increased employee costs[64]. Corporate Governance and Compliance - The company has adhered to corporate governance principles and complied with relevant laws and regulations impacting its business operations[100]. - The audit committee reviewed the audited annual results, confirming compliance with applicable accounting standards[119]. - The financial statements for the year ending December 31, 2024, were approved by the board on March 28, 2025[120]. Future Outlook and Strategy - The company plans to continue enhancing its innovation capabilities and accelerating product development to maintain its leading position in the industry[49]. - The company aims to maximize shareholder returns by actively seeking investment opportunities and diversifying its business strategy to reduce operational risks[96]. - The company is committed to creating a sustainable business without compromising the environment, investing in energy-saving technologies to reduce carbon emissions[99]. - The company will continue to optimize production and sales models to consolidate and further expand its global market share[97]. Events and Announcements - The annual general meeting for 2025 is scheduled for May 28, 2025[117]. - No significant events affecting the group occurred after December 31, 2024[111]. - No shares of the company were purchased, sold, or redeemed by the company or any of its subsidiaries during the fiscal year ending December 31, 2024[108].

Core Viewpoint - The approval of the innovative aortic branch reconstruction stent system by the National Medical Products Administration (NMPA) marks a significant advancement in medical technology, providing a standardized tool for clinicians to address complex aortic arch diseases [1] Company Summary - Xianjian Technology (01302) experienced a stock price increase of over 3% in early trading, with a current price of 1.66 HKD and a trading volume of 24.8849 million HKD [1] - The newly approved product is the world's first aortic-branch stent system specifically designed for chimney technique reconstruction, consisting of Longuette skirt stent and Ankura Pro aortic main stent system [1] Industry Summary - The innovative product addresses dual challenges of leakage and occlusion associated with chimney techniques, enhancing the clinical advantages of this method [1] - The system aims to improve efficiency and precision in treating aortic arch diseases, ultimately benefiting patients with better clinical outcomes [1]

Summary of Conference Call Company and Industry - The conference call discusses a medical device company focused on structural heart disease interventions and related products, particularly in the context of the Chinese and international markets. Key Points and Arguments Market Growth and Trends - The expected natural growth rate for the structural heart disease market in China, Europe, and the US is around 15% to 20%, while emerging markets may see growth between 5% to 10% [5][6] - The company anticipates that the domestic market could reach a growth level of around 7% to 10% in the near future, with price reductions expected to be moderate due to competitive dynamics among three major players [8][6] Product Development and Innovation - The company is actively developing new products, including a focus on AI applications in surgical robotics, although current capabilities are still in early stages [3][4] - There is a significant emphasis on expanding the product pipeline, with expectations for several new products to be launched by 2026, including advanced stents and other vascular devices [13][16] - The company is also exploring the development of absorbable stents, which are currently under scrutiny in the academic community regarding their efficacy compared to traditional devices [10][24] Competitive Landscape - The competitive landscape remains stable, with the company maintaining a market share of approximately one-third alongside competitors [7][6] - The company is aware of the increasing number of competitors entering the market but believes that the overall market dynamics will remain favorable for established players [6][7] International Expansion - The company is planning to expand its international presence, particularly in the structural heart disease segment, with a focus on leveraging existing products that have been successful domestically [15][18] - There is a strategy to ensure that products launched in China will follow a similar timeline for international approvals, enhancing the company's global footprint [16][18] Financial Considerations - The company has a high R&D investment ratio of over 20%, which is among the highest in the industry, indicating a strong commitment to innovation [19][20] - Future profit margins may face pressure due to increased promotional expenses associated with new product launches, but the company expects to manage these costs effectively [21][22] Regulatory and Policy Environment - The company anticipates potential regulatory tightening in the PFO (Patent Foramen Ovale) market, which could temporarily slow growth before resuming [25] - The overall market sentiment is cautious, with expectations of continued uncertainty in the domestic market due to regulatory changes [34] Strategic Planning - The company is considering potential mergers and acquisitions to enhance its product offerings and market reach, depending on available resources [31] - There is an ongoing focus on maintaining a balance between product development and shareholder returns, with a commitment to share buybacks when appropriate [32] Conclusion - The company is positioned as a leader in innovation within the structural heart disease market, with a robust pipeline and strategic plans for both domestic and international growth [34]

Summary of Conference Call Company and Industry Overview - The conference call focused on a medical technology company specializing in innovative vascular products, particularly in the field of stents and related devices. The company is optimistic about its product pipeline and market potential in both domestic and international markets [1][3][9]. Key Points and Arguments 1. **Product Launches and Innovations** - The company is set to launch three major innovative product combinations, including the "Lung Stent," "Open Stent," and "Chest Combination Stent," expected to receive regulatory approval in 2020 [2]. - The "Iron Horse" revolutionary absorbable stent has shown promising results in clinical trials, enhancing its safety and efficacy profile [2][23]. 2. **International Expansion** - The company has established a strong international presence, particularly in Europe, the United States, and Asia-Pacific regions, with international revenue growth projected to accelerate in 2023 and 2024 [3][9]. - The international business is expected to contribute significantly to overall revenue growth, with a diverse product portfolio tailored to different regional needs [9][30]. 3. **Market Dynamics and Growth Potential** - The domestic market for vascular devices is characterized by a high patient volume but low treatment survival rates, indicating substantial growth potential [5]. - The company anticipates that the overall industry will maintain a high growth rate driven by increasing incidence rates of vascular diseases and advancements in minimally invasive technologies [5]. 4. **Competitive Landscape** - The company faces competition from foreign brands, which currently hold a significant market share. However, there is considerable room for domestic products to gain traction [6]. - The company aims to outperform industry growth rates through innovative product offerings and strategic pricing adjustments [6][17]. 5. **Financial Performance and Projections** - The company expects to recover its gross margin quickly following the launch of new products, which are anticipated to have higher utilization rates compared to traditional offerings [8]. - The financial outlook for 2025 is optimistic, with expectations of significant contributions from new product launches and a comprehensive treatment approach for aortic diseases [41][42]. Additional Important Insights - **Regulatory and Market Challenges** - The company is navigating regulatory challenges, particularly in obtaining CE marking for its products in the European market, which is crucial for international sales [21][35]. - Pricing strategies for new products will be carefully considered to mitigate risks associated with potential price reductions in existing product lines [20][21]. - **Research and Development Focus** - The company is committed to continuous innovation, with a strong emphasis on R&D to develop next-generation products that meet evolving market needs [28][41]. - Collaboration with healthcare professionals and institutions is a key strategy for product adoption and market penetration [30][33]. - **Future Outlook** - The company is positioned to be a leader in the vascular device market, with a unique product offering that addresses a wide range of patient needs [42]. - The upcoming years, particularly 2025, are seen as pivotal for the company, with multiple product launches expected to solidify its market position [41][42].

Investment Rating - The report gives a "Buy" rating for the company, with a target price of HKD 1.80 per share, based on a 21x PE valuation for 2025 [52][123]. Core Insights - The company is positioned for long-term growth in the cardiovascular intervention field, with expected revenues of CNY 12.56 billion, CNY 16.87 billion, and CNY 20.76 billion for 2024, 2025, and 2026 respectively [52][123]. - The company has a strong pipeline of innovative products, including three major aortic products that are expected to be approved soon, enhancing its competitive edge [44][42]. - The company has demonstrated a robust international expansion, with overseas revenue reaching CNY 2.75 billion in 2023, a year-on-year increase of 36% [116][117]. Summary by Sections Company Overview - The company focuses on the development of innovative medical devices for cardiovascular interventions, with a strong patent portfolio and a significant market presence in over 120 countries [73][116]. - In 2023, the company achieved revenue of CNY 12.67 billion, a year-on-year increase of 15.5%, driven primarily by sales of congenital heart disease occluders and covered stents [98][51]. Product Lines - The company has three main product lines: structural heart disease, peripheral vascular disease, and electrophysiology, with structural heart disease contributing CNY 4.96 billion in revenue, accounting for 39.1% of total revenue [98][75]. - The peripheral vascular business generated CNY 7.07 billion, representing 55.8% of total revenue, with significant growth in aortic covered stents [98][75]. Market Dynamics - The report highlights the increasing demand for aortic interventions, with the domestic market for aortic stents expected to grow significantly due to rising awareness and the shift towards minimally invasive procedures [22][24]. - The company is well-positioned to capture market share in the aortic stent segment, with a competitive advantage due to its innovative product offerings and strong clinical data [30][42]. Financial Performance - The company reported a gross margin of 78.6% in 2023, which is competitive compared to industry peers, and anticipates higher profitability with the launch of new innovative products [11][12]. - The financial forecast indicates a decline in net profit for 2023, but a rebound is expected in subsequent years, with projected growth rates of 12%, 27%, and 25% for 2024, 2025, and 2026 respectively [52][123]. Innovation and R&D - The company has developed a revolutionary iron-based absorbable stent technology, which combines the support of metal stents with the absorbability of biodegradable materials, showing promising clinical results [14][48]. - The iron-based stent has completed a successful III phase clinical trial, demonstrating high safety and efficacy, which is expected to enhance its market potential [111][130].

Financial Performance - The company reported revenue of approximately RMB 652.8 million for the six months ended June 30, 2024, representing an increase of about 2.1% compared to RMB 639.5 million for the same period in 2023[10]. - Gross profit for the same period was RMB 515.4 million, also reflecting a 2.1% increase from RMB 504.8 million year-on-year[8]. - Operating profit decreased by 20.8% to RMB 202.0 million, down from RMB 255.2 million in the previous year[8]. - Net profit attributable to the company's owners was approximately RMB 205.6 million, a decrease of 6.6% from RMB 220.2 million in the prior year[10]. - The company's basic and diluted earnings per share were RMB 4.6 cents, down 6.1% from RMB 4.9 cents in the same period last year[8]. - The company reported a net income tax expense of RMB 22,837,000 for the six months ended June 30, 2024, compared to RMB 43,770,000 in 2023, indicating a decrease of approximately 47.8%[113]. - The company reported a total comprehensive income of RMB 220,164,000 for the period, compared to RMB 40,523,000 in the same period last year, reflecting a significant increase[100]. Asset and Liability Management - Non-current assets increased by 5.5% to RMB 2,600.9 million, compared to RMB 2,465.2 million as of December 31, 2023[8]. - Total assets rose by 2.6% to RMB 4,819.6 million, up from RMB 4,696.4 million at the end of 2023[8]. - The total current assets amounted to approximately RMB 2,218.6 million, a slight decrease from RMB 2,231.1 million as of December 31, 2023[29]. - The total current liabilities as of June 30, 2024, were approximately RMB 826.5 million, up from RMB 770.1 million as of December 31, 2023[29]. - The company’s total equity as of June 30, 2024, was RMB 3,256,427,000, up from RMB 3,243,328,000 at the end of June 2023[100]. Sales and Market Performance - The company’s domestic sales decreased by approximately 4.7%, while overseas sales increased by approximately 29.8% year-on-year[10]. - The company’s revenue from mainland China accounted for about 75.1% of total revenue, down from 80.4% in the same period last year[10]. - Revenue from the structural heart disease business was approximately RMB 271.2 million, an increase of about 11.2% from RMB 243.9 million in the same period of 2023[14]. - Revenue from the peripheral vascular business was approximately RMB 380.7 million, reflecting a 5.0% increase from RMB 362.7 million in the same period of 2023[14]. Expenses and Cost Management - Sales and distribution expenses increased by approximately 25.8% from RMB 119.2 million for the six months ended June 30, 2023, to RMB 150.0 million for the six months ended June 30, 2024[19]. - Administrative expenses rose by approximately 21.6% from RMB 59.7 million to RMB 72.6 million during the same period, primarily due to increased employee costs related to share-based payments[20]. - Research and development expenses increased by approximately 26.5% from RMB 110.6 million to RMB 139.9 million, with total R&D costs rising to RMB 204.2 million, a 26.1% increase[21]. Investment and Financing Activities - The company invested $20.0 million in Ally Bridge Group Global Life Science Capital Partners V, L.P., with a fair value of approximately RMB 192.3 million as of June 30, 2024, representing 4.0% of total assets[18]. - The company raised bank loans amounting to RMB 99,000,000 during the reporting period, which was not present in the previous year[100]. - The company incurred a loss of RMB 18,243,000 from fair value changes in mixed funds for the six months ended June 30, 2024, compared to a loss of RMB 296,000 in 2023[111]. Corporate Governance and Compliance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange and has complied with all provisions for the six months ending June 30, 2024, except for the deviation regarding the roles of the Chairman and CEO[49]. - The board consists of six directors, including two executive directors, one non-executive director, and three independent non-executive directors, ensuring at least one independent director has appropriate professional qualifications[50]. - The audit committee, composed of three independent non-executive directors, has reviewed the interim results for the six months ending June 30, 2024, confirming compliance with relevant accounting standards and regulations[52]. Share-Based Payments and Stock Options - The company recognized approximately RMB 40,626,000 in share-based payment expenses for the stock option plans during the six months ended June 30, 2024, compared to RMB 25,524,000 in the same period of 2023[149]. - The total number of shares that may be issued upon the exercise of options granted under the share option plan is capped at 462,929,240 shares, which does not exceed 10% of the issued share capital as of September 17, 2021[62]. - The company has a performance-based vesting schedule for stock options, with varying percentages based on performance targets[72]. Research and Development - The company submitted 80 patent applications and successfully obtained approval for 69 patents during the six months ended June 30, 2024, bringing the total effective patent applications to 2,198, with 1,008 approved[13]. - The company is currently in the clinical follow-up phase for the thoracoabdominal aortic stent graft system, which has completed a one-year clinical follow-up in China[14]. - New product research and development expenses amounted to RMB 64,302,000 for the six months ended June 30, 2024, compared to RMB 51,320,000 in 2023, marking an increase of about 25.3%[118].

Financial Performance - For the six months ended June 30, 2024, the revenue was approximately RMB 652.8 million, an increase of about 2.1% compared to RMB 639.5 million for the same period in 2023[2]. - The gross profit for the same period was approximately RMB 515.4 million, reflecting a growth of about 2.1% from RMB 504.8 million in the previous year[2]. - The net profit attributable to the owners of the company was approximately RMB 205.6 million, a decrease of about 6.6% from RMB 220.2 million in the same period of 2023, primarily due to increased employee costs and reduced foreign exchange gains[2]. - The operating profit for the six months was RMB 202.0 million, down from RMB 255.2 million in the same period last year[4]. - The company reported a basic and diluted earnings per share of RMB 4.6 cents, down from RMB 4.9 cents in the same period last year[4]. - The company reported a pre-tax profit of RMB 208,645 thousand for the six months ended June 30, 2024, down from RMB 256,421 thousand for the same period in 2023[11][12]. - The company’s net profit attributable to shareholders was approximately RMB 205.6 million, a decrease of about RMB 14.6 million or approximately 6.6% compared to RMB 220.2 million in the same period of 2023[39]. - The company’s net profit attributable to shareholders decreased by approximately 8.6% from RMB 255.5 million for the six months ended June 30, 2023, to approximately RMB 233.6 million for the six months ending June 30, 2024[58]. - Excluding non-recurring items, the net profit attributable to shareholders decreased from approximately RMB 220.2 million to approximately RMB 205.6 million, a decline of about 6.6%[58]. Revenue Breakdown - For the six months ended June 30, 2024, total external sales amounted to RMB 652,831 thousand, with structural heart disease business contributing RMB 271,250 thousand, peripheral vascular business RMB 380,725 thousand, and electrophysiology business RMB 856 thousand[11]. - Revenue from the structural heart disease business was approximately RMB 271.2 million, representing an increase of about 11.2% compared to RMB 243.9 million in the same period of 2023[44]. - Revenue from the peripheral vascular business was approximately RMB 380.7 million, an increase of about 5.0% compared to RMB 362.7 million in the same period of 2023[45]. - Revenue from the electrophysiology business significantly decreased by approximately 97.3%, contributing only RMB 0.9 million compared to RMB 32.9 million in the same period of 2023[46]. - Domestic sales decreased by approximately 4.7%, while overseas sales increased by approximately 29.8% compared to the same period in 2023, driven by the company's active overseas expansion and effective marketing strategies[39]. Assets and Liabilities - The total assets as of June 30, 2024, were RMB 2,600.9 million, compared to RMB 2,465.2 million as of December 31, 2023[5]. - The total liabilities for the operating segments as of June 30, 2024, were RMB 322,641 thousand, compared to RMB 317,411 thousand as of December 31, 2023[14]. - The company's cash and cash equivalents decreased to RMB 832.6 million from RMB 979.3 million as of December 31, 2023[5]. - Trade receivables as of June 30, 2024, total RMB 122,173,000, an increase of 16.2% from RMB 105,185,000 as of December 31, 2023[29]. - Other receivables and prepayments amount to RMB 505,394,000 as of June 30, 2024, up from RMB 463,041,000 as of December 31, 2023, reflecting an increase of 9.1%[30]. - Trade payables as of June 30, 2024, are RMB 94,313,000, a decrease of 24.0% from RMB 124,086,000 as of December 31, 2023[33]. - The current liabilities totaled approximately RMB 826.5 million as of June 30, 2024, compared to RMB 770.1 million as of December 31, 2023[61]. - The company's debt-to-asset ratio was approximately 2.9% as of June 30, 2024, compared to zero as of December 31, 2023[64]. Research and Development - The company’s research and development expenses for the six months ended June 30, 2024, totaled RMB 139,926 thousand, compared to RMB 110,607 thousand for the same period in 2023[11][12]. - Research and development expenses increased by approximately 26.5% from about RMB 110.6 million for the six months ended June 30, 2023, to about RMB 139.9 million for the six months ended June 30, 2024[53]. - The company submitted 80 patent applications and successfully obtained 69 patents during the six months ended June 30, 2024, bringing the total to 2,198 effective patent applications, with 1,008 patents granted as of June 30, 2024[42]. Strategic Initiatives - The company has received regulatory approvals for several innovative medical devices, including the DiAcuTM biopsy needle and HeartRTM occluder, enhancing its product portfolio and market competitiveness[41]. - The company is currently in the clinical trial phase for several products, including the X-ClipTM transcatheter mitral valve clip system, which is expected to expand its offerings in the cardiovascular market[41]. - The group aims to identify growth opportunities within the healthcare sector and seeks strategic partnerships to enhance its product line and expand its business scale[66]. - The group is focusing on upgrading its left atrial appendage occluder to meet the growing treatment demand, with expectations of increasing global market share[72]. - The group is optimistic about the market performance of its domestic pacemaker series due to significant unmet demand for pacemaker implantation in China[74]. - The company is actively seeking collaboration and investment opportunities with high-growth potential enterprises in the global healthcare sector[80]. Corporate Governance and Compliance - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value[82]. - The audit committee reviewed the interim results, confirming compliance with relevant accounting standards and regulations[84].